OBJECTIVE: To test the validity and reliability of a new measure of clinical impairment in primary progressive aphasia (PPA), the Progressive Aphasia Severity Scale (PASS), and to investigate relationships with MRI-based cortical thickness biomarkers for localizing and quantifying the severity of anatomic abnormalities. METHODS: Patients with PPA were rated using the PASS and underwent performance-based language testing and MRI scans that were processed for cortical thickness measures. RESULTS: The level of impairment in PASS fluency, syntax/grammar, and word comprehension showed strong specific correlations with performance-based measures of these domains of language, and demonstrated high interrater reliability. Left inferior frontal thinning correlated with impairment in fluency and grammar/syntax, while left temporopolar thinning correlated with impairment in word comprehension. Discriminant function analysis demonstrated that a combination of left inferior frontal, left temporopolar, and left superior temporal sulcal thickness separated the 3 PPA subtypes from each other with 100% accuracy (87% accuracy in a leave-one-out analysis). CONCLUSIONS: The PASS, a novel measure of the severity of clinical impairment within domains of language typically affected in PPA, demonstrates reliable and valid clinical-behavioral properties. Furthermore, the presence of impairment in individual PASS domains demonstrates specific relationships with focal abnormalities in particular brain regions and the severity of impairment is strongly related to the severity of anatomic abnormality within the relevant brain region. These anatomic imaging biomarkers perform well in classifying PPA subtypes. These data provide robust support for the value of this novel clinical measure and the new imaging measure as markers for potential use in clinical research and trials in PPA.
OBJECTIVE: To test the validity and reliability of a new measure of clinical impairment in primary progressive aphasia (PPA), the Progressive Aphasia Severity Scale (PASS), and to investigate relationships with MRI-based cortical thickness biomarkers for localizing and quantifying the severity of anatomic abnormalities. METHODS:Patients with PPA were rated using the PASS and underwent performance-based language testing and MRI scans that were processed for cortical thickness measures. RESULTS: The level of impairment in PASS fluency, syntax/grammar, and word comprehension showed strong specific correlations with performance-based measures of these domains of language, and demonstrated high interrater reliability. Left inferior frontal thinning correlated with impairment in fluency and grammar/syntax, while left temporopolar thinning correlated with impairment in word comprehension. Discriminant function analysis demonstrated that a combination of left inferior frontal, left temporopolar, and left superior temporal sulcal thickness separated the 3 PPA subtypes from each other with 100% accuracy (87% accuracy in a leave-one-out analysis). CONCLUSIONS: The PASS, a novel measure of the severity of clinical impairment within domains of language typically affected in PPA, demonstrates reliable and valid clinical-behavioral properties. Furthermore, the presence of impairment in individual PASS domains demonstrates specific relationships with focal abnormalities in particular brain regions and the severity of impairment is strongly related to the severity of anatomic abnormality within the relevant brain region. These anatomic imaging biomarkers perform well in classifying PPA subtypes. These data provide robust support for the value of this novel clinical measure and the new imaging measure as markers for potential use in clinical research and trials in PPA.
Authors: Rahul S Desikan; Florent Ségonne; Bruce Fischl; Brian T Quinn; Bradford C Dickerson; Deborah Blacker; Randy L Buckner; Anders M Dale; R Paul Maguire; Bradley T Hyman; Marilyn S Albert; Ronald J Killiany Journal: Neuroimage Date: 2006-03-10 Impact factor: 6.556
Authors: John C Morris; Sandra Weintraub; Helena C Chui; Jeffrey Cummings; Charles Decarli; Steven Ferris; Norman L Foster; Douglas Galasko; Neill Graff-Radford; Elaine R Peskind; Duane Beekly; Erin M Ramos; Walter A Kukull Journal: Alzheimer Dis Assoc Disord Date: 2006 Oct-Dec Impact factor: 2.703
Authors: Maria Luisa Gorno-Tempini; Nina F Dronkers; Katherine P Rankin; Jennifer M Ogar; La Phengrasamy; Howard J Rosen; Julene K Johnson; Michael W Weiner; Bruce L Miller Journal: Ann Neurol Date: 2004-03 Impact factor: 10.422
Authors: Bradford C Dickerson; Scott M McGinnis; Chenjie Xia; Bruce H Price; Alireza Atri; Melissa E Murray; Mario F Mendez; David A Wolk Journal: CNS Spectr Date: 2017-02-15 Impact factor: 3.790
Authors: Jessica A Collins; Victor Montal; Daisy Hochberg; Megan Quimby; Maria Luisa Mandelli; Nikos Makris; William W Seeley; Maria Luisa Gorno-Tempini; Bradford C Dickerson Journal: Brain Date: 2016-12-31 Impact factor: 13.501
Authors: Jordi A Matías-Guiu; María Nieves Cabrera-Martín; Teresa Moreno-Ramos; María Valles-Salgado; Marta Fernandez-Matarrubia; José Luis Carreras; Jorge Matías-Guiu Journal: J Neurol Date: 2015-04-11 Impact factor: 4.849
Authors: M-Marsel Mesulam; Bradford C Dickerson; Janet C Sherman; Daisy Hochberg; R Gilberto Gonzalez; Keith A Johnson; Matthew P Frosch Journal: N Engl J Med Date: 2017-01-12 Impact factor: 91.245
Authors: Chenjie Xia; Sara J Makaretz; Christina Caso; Scott McGinnis; Stephen N Gomperts; Jorge Sepulcre; Teresa Gomez-Isla; Bradley T Hyman; Aaron Schultz; Neil Vasdev; Keith A Johnson; Bradford C Dickerson Journal: JAMA Neurol Date: 2017-04-01 Impact factor: 18.302